Effectiveness for endothelial function after administration of tadarafil for men with urinary and sexual symptoms

Effectiveness for endothelial function after administration of tadarafil for men with urinary and sexual symptoms - Effectiveness for endothelial function after administration of tadarafil for men with urinary and sexual symptoms

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009580

Enrollment

Registered

2013-01-01

Start date

2013-03-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

benign prostatic hyperplasia

Interventions

recieved tadalafil at once a day morning during 3 months

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Even if received alfa blocker over 4 weeks, IPSS score was over 8 points and QOL index was over 2 points.

Exclusion criteria

Exclusion criteria: 1 Patients Received nitrate drug 2 Patients has organic disease other than BPH, that was prostate cancer,bladder tumor, bladder stone, prostatitis, urethral stenosis et al. 3 Patients were performed urological surgery before 6 months. 4 Patients have active urinary infection. 5 Patients has neurogenic bladder. 6 Patients has severe ischemic coronary disease, cerebrovascular accident, liver dysfunction, renal dysfunction. 7 Patients has hypotension. 8 Doctor has other patients deemed inappropriate.

Design outcomes

Primary

Measure	Time frame
Evaluation of the vascular endothelial function before and after recieved tadalafil at 5mg a day 12 weeks.	—

Countries

Japan

Contacts

Public ContactKazuhiko

Kawasaki medical school Urology

k-fuku@med.kawasaki-m.ac.jp086-462-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026